Senores Pharmaceuticals Acquires ANDAs From Teva Pharmaceuticals USA, Inc.

Senores Pharmaceuticals Acquires ANDAs from Teva Using IPO Proceeds

Senores Pharmaceuticals has announced the acquisition o […] The post Senores Pharmaceuticals Acquires ANDAs from Teva Using IPO Proceeds first appeared on GeneOnline News. The post Senores Pharmaceuticals Acquires ANDAs from Teva Using IPO Proceeds appeared first on GeneOnline News.

Senores Pharmaceuticals acquires ANDAs from Teva Pharmaceuticals USA - Express Pharma

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, USA (SPI), has signed an agreement to acquire two products of USFDA-approved Abbreviated New Drug Applications from Teva Pharmaceuticals USA.  The addressable opportunity of the acquired ANDAs in the USA is ~USD 38 million (MAT December 2024)* as per IQVIA and ~USD 120 Mn (MAT June 2025)# as per the speciality data aggregator Symphony.  The acquisition wi…

Senores Pharmaceuticals acquires ANDAs from Teva Pharmaceuticals USA, Inc.

Ahmedabad, India, August 13, 2025 – Senores Pharmaceuticals Limited (“SPL”), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (“SPI”), has signed an agreement today to acquire two products of USFDA-approved Abbreviated New Drug Applications (“ANDAs”) from Teva Pharmaceuticals USA, Inc. The addressable opportunity of the acquired ANDAs in the USA is ~USD 38 Mn (MAT December 2024)* as per IQVIA and ~USD 120 Mn (MAT June 2025)…